INK 128 (CAS 1224844-38-5)
QUICK LINKS
INK 128 is a small molecule inhibitor that is extensively studied in the field of cancer research due to its ability to target the mechanistic target of rapamycin (mTOR) pathway. This compound is involved in inhibiting both mTORC1 and mTORC2 complexes, which are critical regulators of cell growth, proliferation, and survival. Researchers use INK 128 to understand the effects of mTOR inhibition in various cellular processes, including autophagy, protein synthesis, and metabolism. The compound is also instrumental in studies that explore the role of the mTOR pathway in the development of resistance to anticancer drugs. By utilizing INK 128, scientists can dissect the complex signaling networks that contribute to tumorigenesis. Additionally, the role of INK 128 in modulating the immune response is a subject of interest, particularly in the context of tumor microenvironment interactions.
INK 128 (CAS 1224844-38-5) References
- Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. | García-García, C., et al. 2012. Clin Cancer Res. 18: 2603-12. PMID: 22407832
- The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells. | Lou, HZ., et al. 2014. Biochem Biophys Res Commun. 450: 973-8. PMID: 24971544
- The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. | Li, C., et al. 2015. Cancer Biol Ther. 16: 34-42. PMID: 25692620
- Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo. | Jiang, SJ. and Wang, S. 2015. Tumour Biol. 36: 8177-84. PMID: 25990456
- Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment. | Heinzen, D., et al. 2019. Int J Mol Sci. 20: PMID: 31510109
- PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. | Mpilla, G., et al. 2019. Cancers (Basel). 11: PMID: 31795447
- HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway. | Chen, J., et al. 2019. Aging (Albany NY). 11: 10839-10860. PMID: 31796646
- Evolution of PIKK family kinase inhibitors: A new age cancer therapeutics. | Shaik, A. and Kirubakaran, S. 2020. Front Biosci (Landmark Ed). 25: 1510-1537. PMID: 32114443
- Metabolic characterization of a paused-like pluripotent state. | Sousa, MI., et al. 2020. Biochim Biophys Acta Gen Subj. 1864: 129612. PMID: 32272203
- Modulation of mTOR and epigenetic pathways as therapeutics in gallbladder cancer. | Yang, D., et al. 2021. Mol Ther Oncolytics. 20: 59-70. PMID: 33575471
- Inhibition of NLRP3 Inflammasome Activation and Pyroptosis in Macrophages by Taraxasterol Is Associated With Its Regulation on mTOR Signaling. | Yang, F., et al. 2021. Front Immunol. 12: 632606. PMID: 33679781
- 4sc-202 and Ink-128 cooperate to reverse the epithelial to mesenchymal transition in OSCC. | Yang, X., et al. 2022. Oral Dis. 28: 2139-2148. PMID: 33772986
- Senescence-associated tumor growth is promoted by 12-Lipoxygenase. | Patil, S., et al. 2022. Aging (Albany NY). 14: 1068-1086. PMID: 35158337
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
INK 128, 5 mg | sc-364511 | 5 mg | $315.00 | |||
INK 128, 50 mg | sc-364511A | 50 mg | $1799.00 |